Konstantinos Papavasiliou

Konstantinos Papavasiliou

Auto-generated profile, based on publicly available information

Konstantinos Papavasiliou

Academic Orthopaedic Department, Papageorgiou General Hospital, Aristotle University Medical School, Thessaloniki Ring Road, 56403 Nea Efkarpia, Greece

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2010 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
GPGeorge E Petsatodis
George E Petsatodis
PPPericles P Papadopoulos
Pericles P Papadopoulos
KPKyriakos A Papavasiliou
Kyriakos A Papavasiliou
IHIppokratis G Hatzokos
Ippokratis G Hatzokos
FAFilon Agathangelidis
Filon Agathangelidis
ACAnastasios G Christodoulou
Anastasios G Christodoulou
A total of 109 primary total hip arthroplasties with a cementless alumina ceramic-on-ceramic prosthesis between January 1985 and December 1989. The mean age of the patients at the time of the index arthroplasty was forty-six years. Clinical evaluation was performed with use of the Charnley modification of the Merle d'Aubigné-Postel scale. Seventy-eight patients who had had a total of eighty-five arthroplasties were available for follow-up evaluation at an average of 20.8 years. The patients’ average age at the time of the latest follow-up was 66.8 years. Results: Six hips (six acetabular cups and one femoral stem) in six patients underwent revision. Aseptic loosening of the cup combined with focal osteolysis was the cause of all six revisions. In one patient, the stem was also revised because of aseptic loosening. At the time of final follow-up, the result was excellent (according to the Merle d'Aubigné-Postel scale) in 68% of the hips, good in 19%, fair in 9%, and poor in 4%. The mean Merle d'Aubigné-Postel score improved from 7.9 points preoperatively to 16.9 points postoperatively (p < 0.001). The cumulative rate of survival of the prostheses was 84.4% at 20.8 years. Conclusions: The results of these cementless ceramic-on-ceramic total hip arthroplasties continued to be satisfactory at a minimum of twenty years postoperatively. The improved design of contemporary prostheses and the new generation of ceramic-on-ceramic bearing surfaces may lead to even better long-term results. Level of Evidence: Therapeutic Level IV. See Instructions to Authors for a complete description of levels of evidence....

1 December 2009 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
PDF file
FSFares E Sayegh
Fares E Sayegh
EKEustathios I Kenanidis
Eustathios I Kenanidis
KPKyriakos A Papavasiliou
Kyriakos A Papavasiliou
MPMichael E Potoupnis
Michael E Potoupnis
JKJohn M. Kirkos
John M. Kirkos
GKGeorge A Kapetanos
George A Kapetanos
Background: There are several methods to reduce anterior shoulder dislocations, but few studies have compared the efficacy, safety, and reliability of the different techniques. As a result, deciding which technique to use is seldom based on objective criteria. The aim of the present study was to introduce a new method to reduce an anterior shoulder dislocation, which we have termed “FARES” (Fast, Reliable, and Safe), and to compare it with the Hippocratic and Kocher methods in terms of efficacy, safety, and the intensity of pain felt by the patient during reduction. Methods: Between September 2006 and June 2008, a total of 173 patients with an acute anterior shoulder dislocation (with or without a fracture of the greater tuberosity) were enrolled in the study. One hundred and fifty-four patients, who met all inclusion criteria, were randomly assigned to one of the three study groups (FARES, Hippocratic, and Kocher) and underwent reduction of the dislocation by first or second-year orthopaedic surgery residents. A visual analog scale was used to determine the intensity of the pain felt by the patient during reduction. Results: Demographically, the groups were comparable in terms of age, male:female ratio, the mechanism of dislocation, and the mean time between the injury and the first attempt at reduction. Reduction was achieved with the FARES method in 88.7% of the patients, with the Hippocratic method in 72.5%, and with the Kocher method in 68%. This difference was significant, in favor of the FARES method (p = 0.033). The mean duration of the reduction maneuver was significantly shorter for the FARES method (2.36 ± 1.24 minutes for the FARES method, 5.55 ± 1.58 minutes for the Hippocratic method, and 4.32 ± 2.12 minutes for the Kocher method; p < 0.001), and the mean visual analog pain score was significantly lower for the FARES method (1.57 ± 1.43 for the FARES method, 4.88 ± 2.17 for the Hippocratic method, and 5.44 ± 1.92 for the Kocher method; p < 0.001). No complications were noted in any group. Conclusions: The FARES method is a significantly more effective, faster, and less painful method of reduction of an anterior shoulder dislocation in comparison with the Hippocratic and Kocher methods. It is easily performed by only one physician, it is applicable to anterior shoulder dislocations as well as simple fracture-dislocations, and its use is associated with no more morbidity than that associated with the other two methods. Level of Evidence: Therapeutic Level I. See Instructions to Authors for a complete description of levels of evidence.

1 June 2009 in Spine
Verified
Journal Article
Closed access
FSFares E. Sayegh
Fares E. Sayegh
EKEustathios I. Kenanidis
Eustathios I. Kenanidis
KPKyriakos A. Papavasiliou
Kyriakos A. Papavasiliou
MPMichael E. Potoupnis
Michael E. Potoupnis
JKJohn M. Kirkos
John M. Kirkos
GKGeorge A. Kapetanos
George A. Kapetanos
Prospective, double-blind, randomized, case-control study. To evaluate the efficacy of caudal epidural injections (CEI) containing steroid versus nonsteroid preparations when treating patients suffering from low back pain (LBP) and sciatica. Literature seems to be deprived of well-designed randomized, controlled studies that evaluate the effectiveness of CEI in the treatment of chronic LBP; hence the value of CEI remains still the subject of controversy. Patients suffering from severe chronic LBP and sciatica were randomly allocated into 2 groups. Steroid-group’s patients (n = 93) underwent CEI containing 12 mL of xylocaine 2% and 1 mL of betamethasone dipropionate and betamethasone phosphate (2 + 5) mg/dL. Water for Injection (WFI)-group’s patients (n = 90) underwent CEI containing 12 mL of xylocaine 2% and 8 mL of WFI. Both groups were statistically comparable as far as their demographic data and the cause and duration of symptoms were concerned. Patients answered the Oswestry Disability Index questionnaire and underwent physical examination, before and at 1 week, 1 month, 6 months, and 1 year following the CEI. Symptoms improved in 132 patients (72.1%) following CEI. The mean Oswestry Disability Index questionnaire score of steroid-group’s patients was statistically significant lower than that of the WFI-group at all postinjection re-evaluations. Patients receiving steroid CEI experienced faster relief during the first postinjection week. The Straight Leg Rising test improved in both groups following CEI; this improvement was faster among steroid-group’s patients. Fifty-one patients (27.8%), noticed no improvement 1 week post-CEI and underwent a second CEI (with the same preparation) 7 to 14 days later. Nineteen of them reported improvement; 32 (steroid-group:13, WFI-group:19) did not respond well and underwent operative decompression (n = 15) or spinal fusion (n = 17). CEI containing local anesthetic and steroids or WFI seems to be effective when treating patients with LBP and sciatica. CEI containing steroid preparations demonstrated better and faster efficacy.

16 November 2016 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
PAPer Aspenberg
Per Aspenberg
JMJorge Malouf
Jorge Malouf
Umberto TarantinoUmberto Tarantino
Umberto Tarantino
PGPedro A. García-Hernández
Pedro A. García-Hernández
CCCostantino Corradini
Costantino Corradini
FMFernando Marín
Fernando Marín
Aratide (20 μg/day) with risedronate (35 mg/week) initiated within 2 weeks after fixation of a low-trauma pertrochanteric hip fracture (AO/OTA 31-A1 or 31-A2). The main inclusion criteria were a bone mineral density T-score of ≤−2.0 and 25-OH-vitamin D of ≥9.2 ng/mL. During the first 26 weeks, patients received study medication with oral or injectable placebo plus calcium and vitamin D in a double-blinded fashion. Secondary (Timed Up-and-Go [TUG] test, hip pain, Short Form [SF]-36 health status, and safety) and exploratory (radiographic outcomes and ability to walk) 26-week end points are reported. Results: Of the 224 patients who were randomized, 171 (86 teriparatide, 85 risedronate) were included in the analysis. The mean age was 77 ± 8 years, 77% were female, and 26% had a prior history of low-trauma fracture. The teriparatide group completed the TUG test in a shorter time at 6, 12, 18, and 26 weeks (differences of −5.7, −4.4, −3.1, and −3.1 seconds, respectively; p = 0.021 for the overall difference). They also reported less pain on a visual analog scale immediately after the TUG test at 12 and 18 weeks (adjusted absolute differences of 10.6 and 11.9 mm, respectively; p < 0.05). There were no significant between-group differences in the SF-36 score, Charnley hip pain score, ability to walk, or use of walking aids during follow-up. Radiographic healing at 6, 12, and 26 weeks, mechanical failure of the implant (teriparatide, 7; risedronate, 8), loss of reduction (teriparatide, 2; risedronate, 4), and nonunion (0 cases) were not significantly different. Mild hypercalcemia and hyperuricemia were more frequent with teriparatide. Conclusions: Teriparatide was associated with less pain and a shorter time to complete the TUG test between 6 and 26 weeks compared with risedronate. Other fracture-recovery outcomes were similar. The results should be interpreted with caution as these were secondary end points. Level of Evidence: Therapeutic Level II. See Instructions for Authors for a complete description of levels of evidence....

26 December 2016 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
JMJorge Malouf-Sierra
Jorge Malouf-Sierra
UTUmberto Tarantino
Umberto Tarantino
PGPedro A García-Hernández
Pedro A García-Hernández
CCCostantino Corradini
Costantino Corradini
SOSøren Overgaard
Søren Overgaard
FMFernando Marín
Fernando Marín
We present final results of a study comparing teriparatide 20 μg every day (QD) with risedronate 35 mg once per week (QW) started within 2 weeks after surgery for a pertrochanteric hip fracture. Patients with BMD T‐score ≤ –2.0 and 25OHD ≥9.2 ng/mL were randomized to receive 26‐week double‐dummy treatment plus calcium and vitamin D, followed by 52‐week open‐label treatment with the same assigned active drug. Primary endpoint was change from baseline in lumbar spine (LS) BMD at 78 weeks. Secondary and exploratory endpoints were change in BMD at the proximal femur, function, hip pain (Charnley score and 100 mm Visual Analog Scale [VAS]), quality of life (Short Form‐36), radiology outcomes, and safety. Data were analyzed with mixed models for repeated measures (MMRM) and logistic regression. Totally, 224 patients were randomized; 171 (teriparatide: 86) contributed to the efficacy analyses (mean ± SD age: 77 ± 7.7 years, 77% females). Mean baseline LS, femoral neck (FN), and total hip (TH) T‐scores were –2.16, –2.63, and –2.51, respectively. At 78 weeks, BMD increased significantly more with teriparatide compared to risedronate at the LS (+11.08% versus +6.45%; p < 0.001) and FN (+1.96% versus –1.19%; p = 0.003), with no significant between‐group difference in TH BMD. Timed up‐and‐go (TUG) test was significantly faster with teriparatide at 6, 12, 18, and 26 weeks (differences: –3.2 to –5.9 s; p = 0.045 for overall difference). Hip pain during TUG test by 100 mm VAS was significantly lower with teriparatide at 18 weeks (adjusted difference: –11.3 mm, p = 0.033; –10.0 and –9.3 mm at 12 and 26 weeks, respectively; p = 0.079 for overall difference). Other secondary and exploratory outcomes were not different. Teriparatide group showed two new hip fractures versus seven with risedronate (p = 0.171) and more frequent hypercalcemia and hyperuricemia. In conclusion, 78‐week treatment with teriparatide showed significantly greater increases in LS and FN BMD, less pain, and a faster TUG test versus risedronate. © 2016 American Society for Bone and Mineral Research.

1 September 2012 in Journal of Shoulder and Elbow Surgery
Verified
Journal Article
Closed access
ISIoannis K. Sarris
Ioannis K. Sarris
MKMargaritis J. Kyrkos
Margaritis J. Kyrkos
NGNikiforos Galanis
Nikiforos Galanis
KPKyriakos A. Papavasiliou
Kyriakos A. Papavasiliou
FSFares E. Sayegh
Fares E. Sayegh
GKGeorge A. Kapetanos
George A. Kapetanos